Sovremennye vozmozhnosti profilaktiki insul'tov u bol'nykh fibrillyatsiey predserdiy
- Authors: Baryshnikova G.A1
-
Affiliations:
- Issue: No 6 (2014)
- Pages: 35-42
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/286861
- ID: 286861
Cite item
Open Access
Access granted
Abstract
The article discusses the current approaches to the stroke prevention in patients with atrial fibrillation. The results of ROCKETAF study, illustrating the advantages of the new oral anticoagulant rivaroxaban (Xarelto) over warfarin are presented. With specific references, the issues of risk assessment for thromboembolic complications and bleeding when selecting antithrombotic therapy for the prevention of ischemic cerebrovascular disorders are analyzed. The importance of the treatment compliance of patients treated with oral anticoagulants as a factor that largely determines the efficacy and safety of therapy is emphasized.
Full Text
References
- Гусев Е.И., Скворцова В.И., Стаховская Л.В. Эпидемиология инсульта в России. Журн. неврол. и психиатр. Прил.: Инсульт. 2003;8:4-9.
- Инсульт:диагностика, лечение, профилактика / Под ред. З.А. Суслиной, М.А. Пирадова. М., 2008. С. 11-15;61-66.
- Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22:983-88.
- Wang T.J., Larson M.G., Lloyd-Jones D.M., et al. The lifetime risk of atrial fibrillation: the Framingham Heart Study [abstract]. Circulation. 2002;106:11-456, 7.
- Furie K.L., Goldstein L.B., Albers G.W., et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43:3442-53.
- Camm A.J., Lip G.Y.H., De Caterina R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14:1385-413.
- Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol 2006; 62: 509-11. Hirsh J et al. ACA/ACC Expert Consensus Document on Warfarin Therapy American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. JACC. 2003;41:633-52.
- Hirsh J., et al. ACA/ACC Expert Consensus Document on Warfarin Therapy American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. JACC. 2003;41:633-52.
- Schwarz U.I., Ritchie M.D., Bradford Y. et al. Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 2008;358(10):999-1008.
- Olesen J.B., Lip G.Y., Hansen M.L., et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.
- Camm A.J., Kirchhof P., Lip G.Y.H., et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart. J. 2010;31(19):2369-429.
- ACTIVE Writing Group; on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet. 2006;367:1903-12.
- Weitz, et al. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:234-56.
- Turpie A.G. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler. Thromb. Vasc. Biol. 2007;27(6):1238-47.
- Kubitza D., Becka M., Voith B., Zuehlsdorf M., Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY59-7939, an oral, direct factor Xa inhibitor. Clin. Pharmacol. Ther. 2005;78: 412-21.
- Kubitza D., Becka M., Wensing G., et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur. J. Clin. Pharmacol. 2005;61:873-80.
- Kubitza D., Becka M., Mueck W., Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct Factor Xa inhibitor - are not affected by aspirin. J. Clin. Pharmacol. 2006;46:981-90.
- Kubitza D., Becka M., Mueck W., Zuehlsdorf M. Co-administration of rivaroxaban - a novel, oral, direct Factor Xa inhibitor - and clopidogrel in healthy subjects. Eur. Heart J. 2007;28(Suppl 1):Abstract 189.
- Kubitza D., Becka M., Zuehlsdorf M., Mueck W. No interaction between the novel, oral direct Factor Xa inhibitor BAY59-7939 and digoxin. J. Clin. Pharmacol. 2006;46:Abstract 11.
- Patel M.R., Mahaffey K.W., Garg J., et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011;365:883-91.
- Hankey G.J., Patel M.R., Stevens S.R., et al; ROCKET AF Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012; 11:315-22.
- Laliberte F., et al. Impact of Daily Dosing Frequency on Adherence to Chronic Medications Among Nonvalvular Atrial Fibrillation Patients. Advances in Therapy. 2012;29(8):675-90.
- Diamantopoulos A., Forster F., Evers Th. Real-life treatment persistence with newer oral anticoagulants and potential strokes avoided in patients with atrial fibrillation. ESC Congress. 2013:poster P519.
- Perzborn E., Harwardt M. Recombinant Factor VII apartially reverses the effects of the Factor Xa inhibitor rivaroxaban on thrombin generation, but not the effects of thrombin inhibitors, in vitro. J Thromb Haemost. 2007;5(Suppl 2):Abstract P-W-640.
Supplementary files
